About Cara Therapeutics
Cara Therapeutics is a US biopharmaceutical company founded in 2004 with headquarters in Stamford, Connecticut. It’s an early commercial-stage business with a focus on developing and commercialising treatments for patients suffering from pruritus. In collaboration with Swiss company Vifor Pharma, Cara Therapeutics invented the first FDA-approved injection, KORSUVA™ (CR845/difelikefalin), which serves those with moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing haemodialysis. The company works by selectively targeting peripheral kappa opioid receptors (KORs) and is also developing an oral formulation of difelikefalin, which is in the pipeline. Cara Therapeutics stock is listed on the Nasdaq exchange in New York. Start spread betting or trading CFDs on our Cara Therapeutics share price.
Constituent weightings
Component
Weighting
1 Day
1 Month
3 Month
Trading hours shown in London local time